Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese CROs Geared For Rapid Growth Over Next Few Years

This article was originally published in PharmAsia News

Executive Summary

China is seen by contract research organizations as a site for rapid growth over the next few years as they respond to a high research demand by global drug makers. Most of the largest drug makers are now using drug research contractors in China, drawing on their specialized skills, lower-cost scientists and clinical trial costs much lower than in other countries. With many Chinese CROs being independent or small firms, the country has no firm handle on how much revenue that segment of the drug industry makes. An analyst says those specializing in late-stage research should see rapid growth, probably expanding at 18 percent a year to become a $240 million local industry by 2012. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072924

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel